<DOC>
	<DOC>NCT00324363</DOC>
	<brief_summary>This study is designed to compare the effects of twice-daily exenatide plus oral antidiabetic (OAD) agents and twice-daily placebo plus OAD with respect to glycemic control.</brief_summary>
	<brief_title>Safety and Efficacy of Exenatide in Patients With Type 2 Diabetes Using Metformin or Sulfonylureas and Metformin</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus, Type 2</mesh_term>
	<mesh_term>Exenatide</mesh_term>
	<mesh_term>Metformin</mesh_term>
	<criteria>Treated with a stable dose of one of the following for at least 3 months prior to screening: * &gt;=1000 mg/day immediaterelease metformin; or metformin &gt;=1000 mg/day and sulfonylurea; or sulfonylurea/metformin combination therapy. HbA1c between 7.1% and 11.0%, inclusive. Body Mass Index (BMI) &gt;21 kg/m^2 and &lt;35 kg/m^2. Have participated in this study previously, or any other study using exenatide or GLP1 analogs. Have participated in an interventional, medical, surgical, or pharmaceutical study within 30 days of screening. Have characteristics contraindicating metformin or sulfonylurea use. Have been treated with exogenous insulin for more than 1 week within the 3 months prior to screening. Have used drugs for weight loss within 1 month of screening.</criteria>
	<gender>All</gender>
	<minimum_age>21 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>January 2015</verification_date>
	<keyword>exenatide</keyword>
	<keyword>diabetes</keyword>
	<keyword>Amylin</keyword>
	<keyword>Lilly</keyword>
	<keyword>China</keyword>
</DOC>